CHECKMATE-142

NCT02060188 📎

Regimen

Experimental
Nivolumab 3 mg/kg + ipilimumab 1 mg/kg Q3W × 4 cycles, then nivolumab 3 mg/kg Q2W
Control
single-arm (nivo+ipi cohort)

Population

dMMR/MSI-H metastatic CRC, 2L+, ≥2 prior systemic lines in 76% of patients; 4-year follow-up update.

Key finding

Primary cohort (n=119, 76% had ≥2 prior lines): ORR 55% (95% CI 45.2–63.8), disease control ≥12 weeks 80%; at 4-year follow-up (median 50.9 months), ORR increased to 65% (55–73%), complete response rate 13%; median PFS not reached (38.4 months–NE); median OS not reached; grade 3–4 TRAEs 32%; 4-year update confirmed 37 of 44 responders still ongoing.

Source: PMID 29355075

Timeline

    Guideline citations

    • NCCN Colon (p.59)
    • NCCN Rectal (p.76)